MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. MannKind Corporation (NASDAQ:MNKD) stock opened today at $6.66 and is currently trading at $7.18. The stock showed a positive weekly performance of 5.11%.
Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, reported financial results for the first quarter ended March 31, 2014. First quarter net revenues (equity method) increased 29.1% to $17.9 million.Enzymotec Ltd (NASDAQ:ENZY) stock opened at $18.46, in current trading session and currently is at $14.45, by losing -28.58%. The 52 week range of $13.60 – $35.12. Company’s market capitalization is 324.59 million.
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until May 13, 2014 to file lead plaintiff applications in a securities class action lawsuit against CytRx Corporation (NASDAQ:CYTR). CytRx Corporation (NASDAQ:CYTR) stock is currently trading at $3.44. The EPS of the stock is -1.34. Company’s market capitalization is 191.87 million.
Bristol-Myers Squibb Company (NYSE:BMY) and Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that they have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a Phase 1/2 study. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock opened the session at $13.44, and now is at $15.44. The 52 week range of the Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock remained $10.76 – $38.84 and the day range was $12.85 – $15.63.
Macy’s Inc. (NYSE:M) posted first-quarter fiscal 2014 results, wherein earnings of 60 cents a share came a penny ahead of the Zacks Consensus Estimate, and rose 9% from 55 cents earned in the prior-year quarter. Effective cost management and share repurchase activity provided cushion to the bottom-line. Macy’s, Inc. (NYSE:M) stock is currently trading at $57.75. The EPS of the stock is 3.90. Company’s market capitalization is 21.20 billion.